This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Animal testing remains widespread, but the long history of campaigning against it has made some inroads, with some sectors pioneering alternative methods and scientists highlighting its shortcomings.A ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Global Inhalable Drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period. Mr. Shah Coherent Market Insights Pvt.

Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Glaxo (GSK) delivered earnings and revenue surprises of 9.48% and 2.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?